These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 24802758)

  • 1. A cryptic polyreactive antibody recognizes distinct clades of HIV-1 glycoprotein 120 by an identical binding mechanism.
    Dimitrov JD; Planchais C; Scheel T; Ohayon D; Mesnage S; Berek C; Kaveri SV; Lacroix-Desmazes S
    J Biol Chem; 2014 Jun; 289(25):17767-79. PubMed ID: 24802758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
    Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity.
    Prigent J; Jarossay A; Planchais C; Eden C; Dufloo J; Kök A; Lorin V; Vratskikh O; Couderc T; Bruel T; Schwartz O; Seaman MS; Ohlenschläger O; Dimitrov JD; Mouquet H
    Cell Rep; 2018 May; 23(9):2568-2581. PubMed ID: 29847789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography.
    Dutta M; Liu J; Roux KH; Taylor KA
    J Virol; 2014 Nov; 88(21):12265-75. PubMed ID: 25122783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AIDS/HIV. A boost for HIV vaccine design.
    Burton DR; Weiss RA
    Science; 2010 Aug; 329(5993):770-3. PubMed ID: 20705840
    [No Abstract]   [Full Text] [Related]  

  • 6. Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.
    Rathore U; Purwar M; Vignesh VS; Das R; Kumar AA; Bhattacharyya S; Arendt H; DeStefano J; Wilson A; Parks C; La Branche CC; Montefiori DC; Varadarajan R
    J Biol Chem; 2018 Sep; 293(39):15002-15020. PubMed ID: 30093409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus.
    Liao HX; Lynch R; Zhou T; Gao F; Alam SM; Boyd SD; Fire AZ; Roskin KM; Schramm CA; Zhang Z; Zhu J; Shapiro L; ; Mullikin JC; Gnanakaran S; Hraber P; Wiehe K; Kelsoe G; Yang G; Xia SM; Montefiori DC; Parks R; Lloyd KE; Scearce RM; Soderberg KA; Cohen M; Kamanga G; Louder MK; Tran LM; Chen Y; Cai F; Chen S; Moquin S; Du X; Joyce MG; Srivatsan S; Zhang B; Zheng A; Shaw GM; Hahn BH; Kepler TB; Korber BT; Kwong PD; Mascola JR; Haynes BF
    Nature; 2013 Apr; 496(7446):469-76. PubMed ID: 23552890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12.
    Sterjovski J; Churchill MJ; Ellett A; Wesselingh SL; Ramsland PA; Gorry PR
    Virology; 2012 Oct; 432(2):394-404. PubMed ID: 22818780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged.
    Doores KJ; Fulton Z; Huber M; Wilson IA; Burton DR
    J Virol; 2010 Oct; 84(20):10690-9. PubMed ID: 20702629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
    J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120.
    Spurrier B; Sampson JM; Totrov M; Li H; O'Neal T; Williams C; Robinson J; Gorny MK; Zolla-Pazner S; Kong XP
    Structure; 2011 May; 19(5):691-9. PubMed ID: 21565703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method.
    Evans MC; Phung P; Paquet AC; Parikh A; Petropoulos CJ; Wrin T; Haddad M
    BMC Bioinformatics; 2014 Mar; 15():77. PubMed ID: 24646213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transplanting supersites of HIV-1 vulnerability.
    Zhou T; Zhu J; Yang Y; Gorman J; Ofek G; Srivatsan S; Druz A; Lees CR; Lu G; Soto C; Stuckey J; Burton DR; Koff WC; Connors M; Kwong PD
    PLoS One; 2014; 9(7):e99881. PubMed ID: 24992528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain.
    Utachee P; Nakamura S; Isarangkura-Na-Ayuthaya P; Tokunaga K; Sawanpanyalert P; Ikuta K; Auwanit W; Kameoka M
    J Virol; 2010 May; 84(9):4311-20. PubMed ID: 20164234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection.
    Acharya P; Tolbert WD; Gohain N; Wu X; Yu L; Liu T; Huang W; Huang CC; Kwon YD; Louder RK; Luongo TS; McLellan JS; Pancera M; Yang Y; Zhang B; Flinko R; Foulke JS; Sajadi MM; Kamin-Lewis R; Robinson JE; Martin L; Kwong PD; Guan Y; DeVico AL; Lewis GK; Pazgier M
    J Virol; 2014 Nov; 88(21):12895-906. PubMed ID: 25165110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between natural and heme-mediated antibody polyreactivity.
    Hadzhieva M; Vassilev T; Bayry J; Kaveri S; Lacroix-Desmazes S; Dimitrov JD
    Biochem Biophys Res Commun; 2016 Mar; 472(1):281-6. PubMed ID: 26926563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
    Chakrabarti BK; Pancera M; Phogat S; O'Dell S; McKee K; Guenaga J; Robinson J; Mascola J; Wyatt RT
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):877-87. PubMed ID: 21158699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
    Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
    J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites.
    Acharya P; Luongo TS; Georgiev IS; Matz J; Schmidt SD; Louder MK; Kessler P; Yang Y; McKee K; O'Dell S; Chen L; Baty D; Chames P; Martin L; Mascola JR; Kwong PD
    J Virol; 2013 Sep; 87(18):10173-81. PubMed ID: 23843638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies raised against covalently crosslinked complexes of human immunodeficiency virus type 1 gp120 and CD4 receptor identify a novel complex-dependent epitope on gp 120.
    DeVico AL; Rahman R; Welch J; Crowley R; Lusso P; Sarngadharan MG; Pal R
    Virology; 1995 Aug; 211(2):583-8. PubMed ID: 7544051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.